



Catalog No: BF-17639960

[Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2) Delta
(B.1.617.2) Probe qRT-PCR Kit]

User Manual

Disclaimer: Products are intended for research use only



 www.biofargo.com

 804-529-2296

 contact@biofargo.com



Product Description

Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2) Delta (B.1.617.2)

Probe qRT-PCR Kit is a one-step RT-PCR kit intended for research use in nucleic acid analysis under controlled laboratory conditions using probe-based real-time PCR. Purified RNA is reverse transcribed into cDNA and subsequently amplified using sequence-specific primers and probes.

During amplification, fluorescence signals are generated through probe cleavage, allowing real-time monitoring of amplification under controlled laboratory conditions. The resulting signals may be used for comparative analysis of target nucleic acids.

Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2) Delta (B.1.617.2)

Probe qRT-PCR Kit has the following features:

1. One-step RT-PCR workflow to reduce handling steps and minimize contamination risk.
2. Demonstrates high sensitivity under optimized laboratory conditions.
3. High specificity based on primer-probe design.
4. Includes a non-infectious plasmid-based positive control for assay verification.
5. Compatible with commonly used RNA purification methods.
6. Suitable for research applications including assay development and method evaluation.
7. Broad dynamic range under laboratory conditions.
8. For research use only. Not intended for diagnostic or therapeutic use.

Input Sample Requirements

RNA samples should be prepared using standard nucleic acid purification methods suitable for downstream RT-PCR analysis. Commercially available column-based or magnetic bead-based RNA extraction methods are recommended.



Kit Components

Component Name	Description	Size	Vial	Lid Color
2× One-Step RT-PCR Master Mix	Contains optimized buffer and enzyme mix	500 µL	0.5 mL Vial	Blue
Primer-Probe Powder	Lyophilized target-specific primer and probe set	50 T	1.5 mL Vial	Brown
Positive Control (1E7 copies/µL)	Non-infectious plasmid-based control	0.5 mL	0.5 mL Vial	Yellow
Nuclease-free water / Dilution Buffer	For reaction setup	1 mL	1.5 mL Vial	Green
Manual	Instruction booklet	1 Set	N/A	N/A

Storage and Handling

Reagents are shipped on ice and should be stored at -20°C upon receipt. The kit is stable for at least 12 months when stored under recommended conditions.

Avoid repeated freeze–thaw cycles. All components should be thawed completely at room temperature prior to use, kept on ice during use, and returned to -20°C promptly after use.

Before reaction setup, gently mix thawed components by inversion or brief vortexing and collect contents by quick centrifugation if necessary.



Materials and Equipment Required but not Supplied in the Kit

Unless otherwise indicated, all materials are available through major laboratory suppliers.

Class	Items
General laboratory equipment and consumables	Benchtop microcentrifuge, micropipettes, vortex mixer, disposable powder-free gloves, sterile filter pipette tips
Kit-specific laboratory equipment and consumables	Manual or automated nucleic acid purification systems, real-time PCR instruments and compatible consumables, PCR reaction setup workstation, appropriate control materials for assay verification

Procedural Guidelines

Use purified RNA as starting material.

Perform all procedures at room temperature (20–25°C), unless otherwise specified.

Use sterile, disposable Nuclease-free pipette tips and microcentrifuge tubes.

Wear appropriate personal protective equipment (PPE), including disposable gloves, when handling reagents and RNA.



Procedures

Section 1: Preparation of Control Dilutions

Prepare serial dilutions of the Positive Control to generate a range of concentrations (e.g., 1E1–1E6 copies/ μ L) for assay evaluation.

Note: Due to the high concentration of the Positive Control, dilution steps should be performed in a designated area to avoid contamination. The Positive Control is a non-infectious plasmid construct.

1. Label six microcentrifuge tubes (1–6).
2. Add 45 μ L of Dilution Buffer to each tube.
3. Add 5 μ L of Positive Control (1E7 copies/ μ L) into tube 6 and mix thoroughly.
4. Perform serial 10-fold dilutions by transferring 5 μ L sequentially from tube to tube.
5. Mix each dilution thoroughly and keep on ice until use.

These dilutions may be used for assay performance evaluation.

Section 2: Preparation of Reagents and Controls

6. Primer-Probe Reconstitution

The Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2) Delta (B.1.617.2) Probe qRT-PCR Kit Primer-Probe component is provided in lyophilized form.

Add 165 μ L of Nuclease-free water to reconstitute the lyophilized Primer-Probe Powder.

Mix gently by vortexing for 10 seconds and briefly centrifuge to collect contents.

Keep the reconstituted solution on ice before use.

Store any remaining solution at -20°C and avoid repeated freeze–thaw cycles.

7. Reaction Setup Planning

Determine the number of reactions based on sample number and experimental design.

Include appropriate controls such as:

- Positive Control (for assay verification)
- Negative Control (nuclease-free water)



Adjust total reaction numbers accordingly.

Section 3: qRT-PCR Reaction Setup (20 μ L per reaction)

Prepare the reaction mixture on ice as follows:

Component	Volume
2 \times One-Step RT-PCR Master Mix	10 μ L
Primer-Probe Mix	3 μ L
Template RNA or control	7 μ L
Total	20 μ L

Mix gently and centrifuge briefly.

Perform real-time RT-PCR according to instrument guidelines.

Section 4: PCR Cycling Conditions

1. Perform real-time RT-PCR using the recommended cycling conditions below. Optimization may be required depending on the instrument platform and experimental conditions.

Step	Temperature	Time	Cycles
Reverse Transcription	50°C	10 min	1
Initial Denaturation	95°C	5 min	1
Denaturation	95°C	15 sec	45
Annealing/Extension	60°C	30 sec	45
Extension & Signal Acquisition (FAM channel)	72°C	1 min	45

Section 5: Data Analysis (For Research Use Only)

1. General Data Review



After completion of the RT-PCR run, review amplification plots and ensure that the threshold is set within the exponential phase of amplification and above background signal. For instrument-specific analysis procedures, refer to the corresponding user manual.

2. Control Performance Evaluation

Verify that control reactions perform as expected:

- Positive Control: amplification signal should be observed
- Negative Control (no-template control): no amplification signal

If control performance does not meet expectations, results should not be interpreted and the experiment should be repeated.

3. Quantitative Analysis (Optional)

If quantitative analysis is performed, serial dilutions of the Positive Control may be used to generate a standard curve under laboratory conditions. The relationship between fluorescence signal and target concentration may be used for comparative analysis.

4. Qualitative Assessment (Optional)

Amplification results may be evaluated based on Ct values:

- Ct values may be used for comparative analysis of target signal levels under experimental conditions.
- Absence of amplification or late Ct values may indicate low or undetectable levels

Results should be interpreted within the context of experimental design and research objectives.

5. Important Notice

This kit is intended for research use only. Results are for analytical and investigational purposes and are not intended for diagnostic applications.



Limited Product Warranty

Biofargo warrants that its products meet the specifications stated in the accompanying product documentation at the time of shipment. Warranty coverage is subject to Biofargo's Terms and Conditions of Sale, available at biofargo.com, and may vary depending on product type and region.

This product is intended for **research use only** and is not intended for use in diagnostic or therapeutic procedures in humans or animals.

This product does not contain infectious materials and is intended solely for laboratory research applications.

Users are responsible for determining the suitability of this product for their specific research applications. Biofargo does not guarantee performance under all experimental conditions, as results may vary depending on protocols, sample handling, and laboratory practices.

If you have any questions regarding product selection, application, or warranty coverage, please contact Biofargo technical support via biofargo.com.

- The information provided in this document is subject to change without notice.
- For research use only. Not intended for diagnostic or therapeutic use.
- **DISCLAIMER: TO THE EXTENT PERMITTED BY LAW, BIOFARGO SHALL NOT BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING FROM THE USE OF THIS PRODUCT OR RELATED DOCUMENTATION.**